Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01263028 · ClinicalTrials.gov registry record · NA
Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose
A NA study, sponsored by Kaiser Permanente.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT01263028 is a NA study that was terminated before completion, run by Kaiser Permanente. The registered enrollment target is 6 participants.
The verdict
NCT01263028, a NA study, was terminated before completion, sponsored by Kaiser Permanente.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
Hypothesis: The supplementation of Ergocalciferol (Vitamin D2) to those with Vitamin D deficiency in the Chronic Kidney Disease population requiring recombinant human erythropoietin for the treatment of anemia related to kidney disease will reduce the dose of erythropoietin required to maintain a nonanemic state.
Interventions
- DRUG Ergocalciferol supplementation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01263028
The ClinicalTrials.gov registry entry for NCT01263028 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ergocalciferol supplementation is the first listed.
NCT01263028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01263028 about?
NCT01263028 is a clinical study titled "Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose". Hypothesis: The supplementation of Ergocalciferol (Vitamin D2) to those with Vitamin D deficiency in the Chronic Kidney Disease population requiring recombinant human erythropoietin for the treatment of anemia related to kidney disease will reduce the dose of erythropoietin required to maintain a no...
What is the current status of trial NCT01263028?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2010-08. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01263028?
The interventions under investigation include: Ergocalciferol supplementation (DRUG).
Who is sponsoring clinical trial NCT01263028?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.